STOPPING anticoagulation after atrial fibrillation ablation was linked to less major bleeding in select patients at risk of stroke. In a nationwide Korean cohort, the association was observed among patients with CHA₂DS₂-VA scores of 2 to 4 who had no documented atrial fibrillation recurrence during the first year after the procedure.
Anticoagulation After Ablation at the One-Year Mark
Researchers used South Korea’s National Health Insurance Service database to identify 3,637 patients with CHA₂DS₂-VA scores of at least 2 who remained free of documented recurrence for 12 months after catheter ablation. Prescription coverage at the 12-month mark determined whether patients were classified as continuing or discontinuing oral anticoagulants. The mean age was 60.8 years, and 27.1% of participants were women.
The primary outcome combined stroke, systemic embolism, and major bleeding. Researchers used overlap weighting and adjusted Cox regression to compare outcomes in patients with CHA₂DS₂-VA scores of 2 to 4 and those with scores of 5 or higher.
Major Bleeding and Stroke Risk by CHA₂DS₂-VA Score
Among 3,054 patients with scores of 2 to 4, stopping anticoagulation after ablation was associated with a lower hazard of the composite outcome (hazard ratio [HR], 0.61; 95% confidence interval [CI], 0.38–0.96) and major bleeding (HR, 0.51; 95% CI, 0.29–0.90). The estimate for stroke or systemic embolism was imprecise (HR, 0.73; 95% CI, 0.34–1.58), with the confidence interval spanning both a lower and a higher hazard.
Among the 583 patients with scores of 5 or higher, discontinuation showed no statistically significant association with any outcome. Interaction tests were also nonsignificant (all P > .46), leaving uncertainty about whether the associations differed by stroke risk category.
For clinicians weighing anticoagulation after ablation, the findings quantify a potential bleeding benefit in patients with scores of 2 to 4 who reached one year without documented recurrence. The observational design and wide confidence interval for thromboembolic events leave the safety of discontinuation uncertain, even in that subgroup. The study assessed prescription coverage at one year, so its findings apply to that decision point.
Reference
Lee YS et al. Discontinuation of anticoagulation in patients at relatively high risk of stroke after successful catheter ablation for atrial fibrillation: a nationwide cohort study. JACC Clin Electrophysiol. 2026. doi:10.1016/j.jacep.2026.10.016.